Neurodon
Crown Point
About Neurodon
Neurodon is the only company harnessing and restoring Ca2+ with first-in-class modulators. Neurodon’s compounds have undergone extensive proof-of-concept studies in animal models of diabetes, obesity, neurodegenerative disorders, and rare diseases. There are no competitors in market targeting diseases with Neurodon’s MOA and industry-leading ER stress platform technology. We have 2 candidates in IND-enabling studies and plan to enter the clinic in 2025. Neurodon has raised >$11MM to date through a combination of state and federal grants (e.g. NIH), foundations (e.g. JDRF), partnerships, angel investments, and founder’s funds. Neurodon is currently raising a funding round to fund first in human studies for its diabetes and rare disease programs in 2025.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $9.4M
- Funding stage: Seed
- Last round: Grant (Oct 2023)
- Website: neurodon.net
- Phone: +1 (219) 225-2104
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/neurodon-55872 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.